Librax

Depression, Enterocolitis, Anxiety Disorders + 6 more

Treatment

8 FDA approvals

20 Active Studies for Librax

What is Librax

Chlordiazepoxide

The Generic name of this drug

Treatment Summary

Chlordiazepoxide is a medication used to treat anxiety, seizures, and symptoms related to alcohol withdrawal. It works by calming the brain and nerves and can also cause memory loss.

Librax

is the brand name

image of different drug pills on a surface

Librax Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Librax

Chlordiazepoxide

1966

112

Approved as Treatment by the FDA

Chlordiazepoxide, otherwise known as Librax, is approved by the FDA for 8 uses like Enterocolitis and Irritable Bowel Syndrome .

Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Irritable Bowel Syndrome

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

Irritable Bowel Syndrome (IBS)

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

acute Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Depression

Used to treat Depression in combination with Amitriptyline

Peptic Ulcer Disease

Used to treat Peptic Ulcer Disease in combination with Clidinium

Anxiety

Used to treat moderate to severe anxiety in combination with Amitriptyline

moderate to severe symptoms

Used to treat moderate to severe symptoms in combination with Amitriptyline

Effectiveness

How Librax Affects Patients

Chlordiazepoxide is used to reduce anxiety, induce sleep, increase appetite, and provide mild pain relief. It works by blocking the brain's response to stimulation, and has been linked to the limbic system, which is involved in emotion. Tests on monkeys and rats have shown that it can reduce fear and aggression, even at doses that do not cause sedation.

How Librax works in the body

Chlordiazepoxide works by binding to certain receptor sites in the brain. This increases the action of the neurotransmitter GABA which is responsible for calming down nerve activity. As a result, chlordiazepoxide has sedative, hypnotic, anti-anxiety and muscle relaxant properties.

When to interrupt dosage

The measure of Librax hinges upon the diagnosed affliction, including Syndrome, moderate to severe symptoms and Depression. The amount likewise fluctuates as per the technique of delivery featured in the shown table.

Condition

Dosage

Administration

moderate to severe symptoms

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Depression

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Enterocolitis

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Anxiety Disorders

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Irritable Bowel Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Peptic Ulcer Disease

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Librax.

Common Librax Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Deutetrabenazine

Major

The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Deutetrabenazine.

Ethanol

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Methadone

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Oliceridine

Major

The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Chlordiazepoxide is combined with Oliceridine.

Librax Toxicity & Overdose Risk

The toxic dose of this drug for rats is 537mg/kg when taken orally. Signs of an overdose include difficulty breathing, muscle weakness, and excessive sleepiness.

image of a doctor in a lab doing drug, clinical research

Librax Novel Uses: Which Conditions Have a Clinical Trial Featuring Librax?

Condition

Clinical Trials

Trial Phases

Anxiety Disorders

53 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1

Enterocolitis

0 Actively Recruiting

Irritable Bowel Syndrome

5 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Peptic Ulcer Disease

0 Actively Recruiting

Anxiety

2 Actively Recruiting

Not Applicable

Anxiety

0 Actively Recruiting

Depression

300 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

moderate to severe symptoms

0 Actively Recruiting

Librax Reviews: What are patients saying about Librax?

5

Patient Review

4/20/2013

Librax for Irritable Colon

Librax has been a life saver for me. It's helped me immensely and I'm grateful to have had it prescribed to me by the Mayo Clinic.

5

Patient Review

10/15/2014

Librax for Irritable Colon

I alternate between this drug and Bentyl, depending on which one I need at the moment. They've both been great at helping with my cramping and IBS symptoms. Within 20 minutes, I'm feeling a lot better.

5

Patient Review

3/5/2014

Librax for Irritable Colon

I took this medicine 40 years ago and it stopped me from having surgery on my colon. About 4 years ago my colon started acting up again, so I asked my doctor for Librax. He said that's an old drug and offered a different medication, but I told him I wanted Librax because I know it works.

5

Patient Review

3/19/2013

Librax for Irritable Colon

I've been using this medication for 3 months and, at first, it was amazing. However, the past few weeks my cramps have come back even though I'm still taking the drug.

5

Patient Review

8/4/2013

Librax for Irritable Colon

I've found this to be an effective treatment for my anxiety and stomach issues.

5

Patient Review

1/21/2014

Librax for Irritable Colon

It takes away the muscle pain, but sometimes it doesn't work

5

Patient Review

3/5/2014

Librax for Irritable Colon

This medication completely cured my IBS. It was a one-time treatment that I took for a month, and haven't had any problems since then.

5

Patient Review

10/24/2012

Librax for Irritable Colon

I was finally able to get some much-needed rest. My irritable colon also calmed down and I felt more comfortable overall.

5

Patient Review

11/15/2016

Librax for Irritable Colon

This medication is effective, but I want to stop taking it because of an unknown additive. I'm not sure the best way to safely wean myself off.

5

Patient Review

11/5/2017

Librax for Irritable Colon

This medication is great for when my cramps get bad. Just one pill does the trick and relaxes both me and my colon. I have to be careful not to take too many, though, as that can cause constipation.

5

Patient Review

5/18/2021

Librax for adjunct therapy for irritable bowel syndrome

This was an incredibly effective treatment for my pain and cramps when my IBS flared up. Unfortunately, I can't seem to find it anywhere now. If anyone could help me source it, I would appreciate it immensely.

5

Patient Review

6/9/2022

Librax for Irritable Colon

Librax has been a life-saver for me. It's the only medication that I've tried that's actually helped with my symptoms of irritable bowel syndrome. Without it, my quality of life would be much poorer.

4

Patient Review

5/6/2015

Librax for Irritable Colon

This medication has done wonders for my esophageal spasms. I'm so grateful to have found something that finally works.

4

Patient Review

9/28/2014

Librax for Irritable Colon

This medication is excellent for cramps.

3.7

Patient Review

1/30/2013

Librax for Irritable Colon

After a long and frustrating journey, this was the only medication that provided relief for my IBS. It's great to not have to worry about what I eat. No negative side effects that I've noticed, either.

3.3

Patient Review

1/10/2014

Librax for Irritable Colon

IBS, choking and damage from severe acid reflex are no joke. I also experienced tremors in my right hand and insomnia. This treatment helped me a lot.

3

Patient Review

8/1/2012

Librax for Irritable Colon

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about librax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Librax used for?

"Chlordiazepoxide helps to decrease anxiety and tension.

This medication consists of clidinium and chlordiazepoxide, and is used to treat disorders in the stomach and intestines (such as ulcers, irritable bowel syndrome, bowel infections) in addition to other medications. Clidinium suppresses symptoms of stomach and intestinal cramping, while chlordiazepoxide reduces anxiety and tension."

Answered by AI

Is Librax a sleeping pill?

"This is because it contains the active ingredient chlordiazepoxide which is a type of medicine called a benzodiazepine.

Does Librax 5 mg/2.5 mg make people feel drowsy or sleepy?

Yes, Librax 5 mg/2.5 mg may make you feel drowsy or sleepy."

Answered by AI

Why was Librax taken off the market?

"Valeant Pharmaceuticals has announced a voluntary recall of certain lots of its Librax medication. The recall was initiated due to a stability failure that was discovered during the annual stability program for the product."

Answered by AI

Is Librax used for anxiety?

"The drug Librax is an anticholinergic/antispasmodic drug which works by slowing down the natural movements of the intestines and relaxing the muscles of the stomach and intestines. Chlordiazepoxide, which is also a component of Librax, helps in reducing anxiety by acting on the brain and nerves to produce a calming effect."

Answered by AI

Clinical Trials for Librax

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Have you considered Librax clinical trials?

We made a collection of clinical trials featuring Librax, we think they might fit your search criteria.
Go to Trials
Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Have you considered Librax clinical trials?

We made a collection of clinical trials featuring Librax, we think they might fit your search criteria.
Go to Trials
Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Have you considered Librax clinical trials?

We made a collection of clinical trials featuring Librax, we think they might fit your search criteria.
Go to Trials